Skip to content

SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506001-19-00
Enrollment
10
Registered
2026-08-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

paraganglioma or pheochromocytoma with surgical indication

Brief summary

Presence or absence of a specific 13C6-glucose metabolism profile in patients' plasma

Detailed description

Capillary blood glucose measurement at different sampling times during the study., To identify the optimal time for sampling after administration of 13C6-glucose and the optimal infusion duration., The measured 13C-biomarker level will be compared to the tumor mass determined by preoperative imaging and to the tumor weight during histological analysis., Analysis of the metabolic profile of resected tumors

Interventions

DRUGD-Glucose-13C6

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Presence or absence of a specific 13C6-glucose metabolism profile in patients' plasma

Secondary

MeasureTime frame
Capillary blood glucose measurement at different sampling times during the study., To identify the optimal time for sampling after administration of 13C6-glucose and the optimal infusion duration., The measured 13C-biomarker level will be compared to the tumor mass determined by preoperative imaging and to the tumor weight during histological analysis., Analysis of the metabolic profile of resected tumors

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 11, 2026